Belumosudil to prevent kidney scarring after transplant
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests whether a drug called belumosudil can reduce scarring in the kidney after transplant. Scarring can lead to kidney damage over time, and this study aims to stop that from happening.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are receiving your first or second kidney transplant.
- You are between 18 and 75 years old.
- If you can become pregnant, you must have a negative pregnancy test and use two forms of birth control during the study.
- If you are sexually active and male, you must use effective birth control during and for 90 days after treatment.
- Your most recent antibody test against donated organs must be less than 80%.
- You can take oral medications and follow study guidelines like not eating grapefruit.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether fingolimod can reduce kidney scarring and preserve kidney function after a new kidney transplant. It focuses on people who are in the early period after transplant who may be at risk for scarring in the kidney.
This trial tests whether the drug Belumosudil can help prevent chronic lung rejection in people who recently had a lung transplant and showed signs of early rejection. It may improve long-term lung health.
This trial tests a medication called belatacept to see if it can prevent or treat early antibody-mediated rejection in kidney transplant recipients who have developed new donor-specific antibodies but still have stable kidney function.
This study tests whether a drug called belumosudil can help prevent graft-versus-host disease (GVHD) after a stem cell transplant. It is for people who have had a recent transplant and are at risk for GVHD.
This trial tests a pill called belumosudil to see if it can help people with chronic graft-versus-host disease (a common complication after a stem cell transplant where donor cells attack your body). It is for patients who have symptoms but are not yet on strong immune-suppressing drugs.
This trial looks at replacing standard anti-rejection medicines (tacrolimus, a type of CNI, plus mycophenolate and possibly prednisone) with belatacept in adults who have early kidney graft dysfunction 3–12 months after a kidney transplant. It aims to see if belatacept can control rejection and protect kidney function in the right patients.
Hear when a new Rejection Chronic Renal trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.